Note 1 - Description of Business

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1.

Description of Business

Cleveland BioLabs, Inc. ("

CBLI

" or the "

Company

") is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of Toll-like immune receptor ("

TLR

") activators has applications in radiation protection and oncology. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our most advanced product candidate is entolimod, an immune-stimulatory agent, which we are developing as a medical radiation countermeasure and other indications in radiation oncology.

CBLI was incorporated in Delaware in

June 2003

and is headquartered in Buffalo, New York. CBLI conducts business in the United States ("

U.S.

") and in the Russian Federation ("

Russia

") through

two

subsidiaries:

one

wholly-owned subsidiary, BioLab

612,

LLC (

"BioLab

612"

), which began operations in

2012;

and Panacela Labs, Inc. ("

Panacela

"), which was formed by us and Joint Stock Company "RUSNANO" ("

Rusnano

"), our financial partner in the venture, in

2011.

Unless otherwise noted, references to the "Company," "we," "us," and "our" refer to Cleveland BioLabs, Inc. together with its subsidiaries.

The Company also has an investment in Genome Protection, Inc. ("

GPI

") that is recorded under the equity method of accounting in the accompanying financial statements. The Company has

not

recorded its

50%

share of the losses of GPI through

December 31, 

2019

as the impact would have reduced the Company's equity method investment in GPI below zero, and there are

no

requirements to fund the Company's share of these losses or contribute additional capital as of the date of these statements.